Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Dynavax Technologies Corporation Trends and Insights

Biotech Giants: SG&A Expense Trends from 2014 to 2023

__timestampDynavax Technologies CorporationIntra-Cellular Therapies, Inc.
Wednesday, January 1, 20141776300010337679
Thursday, January 1, 20152218000018187286
Friday, January 1, 20163725700024758063
Sunday, January 1, 20172736700023666957
Monday, January 1, 20186477000030099855
Tuesday, January 1, 20197498600064947625
Wednesday, January 1, 202079256000186363444
Friday, January 1, 2021100156000272611040
Saturday, January 1, 2022131408000358782000
Sunday, January 1, 2023152946000409864000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. has seen a staggering increase in SG&A expenses, growing by approximately 3,860%, from $10.3 million in 2014 to $409.9 million in 2023. In contrast, Dynavax Technologies Corporation's expenses have increased by about 760%, from $17.8 million to $152.9 million in the same timeframe.

This trend highlights the aggressive expansion and operational scaling of Intra-Cellular Therapies, Inc., especially post-2020, where their expenses surged by over 120% annually. Meanwhile, Dynavax Technologies Corporation has maintained a steadier growth trajectory, reflecting a more conservative approach. These insights provide a window into the strategic priorities and market positioning of these two biotech players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025